TY - JOUR
T1 - Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization
AU - Lara-Castillo, Nuria
AU - Zandi, Souska
AU - Nakao, Shintaro
AU - Ito, Yasuhiro
AU - Noda, Kousuke
AU - She, Haicheng
AU - Ahmed, Muna
AU - Frimmel, Sonja
AU - Ablonczy, Zsolt
AU - Hafezi-Moghadam, Ali
N1 - Funding Information:
Supported by National Institutes of Health grant AI050775 and the National Eye Institute core grants EY14104 and EY14793, and American Health Assistance Foundation, Massachusetts Lions Eye Research Fund, Inc., and Research to Prevent Blindness awarded unrestricted funds to the Departments of Ophthalmology at Harvard Medical School and the Medical University of South Carolina; project also funded by the Marion W. and Edward F. Knight Fund (to A.H-M.).
PY - 2009
Y1 - 2009
N2 - Atrial natriuretic peptide (ANP) is a hormone with diuretic, natriuretic, and vasodilatory properties. ANP blocks vascular endothelial growth factor (VEGF) production and signaling in vitro; however, its role in vascular leakage and angiogenesis is unknown. In vitro, retinal barrier permeability (transepithelial electrical resistance (TEER)) was measured in cultured retinal endothelial (HuREC) and retinal epithelial (ARPE-19) cells with VEGF (10 ng/ml), ANP (1 pM to 1 μmol/L), and/or isatin, an ANP receptor antagonist. In vivo, blood-retinal barrier (BRB) leakage was studied using the Evans Blue dye technique in rats treated with intravitreal injections of ANP, VEGF, or vehicle. Choroidal neovascularization was generated by laser injury, and 7 days later, lesion size and leakage was quantitated. ANP significantly reversed VEGF-induced BRB TEER reduction in both HuREC and ARPE-19 cells, modeling the inner and the outer BRB, respectively. Isatin, a specific ANP receptor antagonist, reversed ANP's effect. ANP reduced the response of ARPE-19 cells to VEGF apically but not basolaterally, suggesting polarized expression of the ANP receptors in these cells. ANP's TEER response was concentration but not time dependent. In vivo, ANP significantly reduced VEGF-induced BRB leakage and the size of laser-induced choroidal neovascularization lesions. In sum, ANP is an effective inhibitor of VEGF-induced vascular leakage and angiogenesis in vivo. These results may lead to new treatments for ocular diseases where VEGF plays a central role, such as age-related macular degeneration or diabetic retinopathy.
AB - Atrial natriuretic peptide (ANP) is a hormone with diuretic, natriuretic, and vasodilatory properties. ANP blocks vascular endothelial growth factor (VEGF) production and signaling in vitro; however, its role in vascular leakage and angiogenesis is unknown. In vitro, retinal barrier permeability (transepithelial electrical resistance (TEER)) was measured in cultured retinal endothelial (HuREC) and retinal epithelial (ARPE-19) cells with VEGF (10 ng/ml), ANP (1 pM to 1 μmol/L), and/or isatin, an ANP receptor antagonist. In vivo, blood-retinal barrier (BRB) leakage was studied using the Evans Blue dye technique in rats treated with intravitreal injections of ANP, VEGF, or vehicle. Choroidal neovascularization was generated by laser injury, and 7 days later, lesion size and leakage was quantitated. ANP significantly reversed VEGF-induced BRB TEER reduction in both HuREC and ARPE-19 cells, modeling the inner and the outer BRB, respectively. Isatin, a specific ANP receptor antagonist, reversed ANP's effect. ANP reduced the response of ARPE-19 cells to VEGF apically but not basolaterally, suggesting polarized expression of the ANP receptors in these cells. ANP's TEER response was concentration but not time dependent. In vivo, ANP significantly reduced VEGF-induced BRB leakage and the size of laser-induced choroidal neovascularization lesions. In sum, ANP is an effective inhibitor of VEGF-induced vascular leakage and angiogenesis in vivo. These results may lead to new treatments for ocular diseases where VEGF plays a central role, such as age-related macular degeneration or diabetic retinopathy.
UR - http://www.scopus.com/inward/record.url?scp=73549120865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73549120865&partnerID=8YFLogxK
U2 - 10.2353/ajpath.2009.090439
DO - 10.2353/ajpath.2009.090439
M3 - Article
C2 - 19910509
AN - SCOPUS:73549120865
VL - 175
SP - 2343
EP - 2350
JO - American Journal of Pathology
JF - American Journal of Pathology
SN - 0002-9440
IS - 6
ER -